56 results
8-K
EX-99.1
GRTS
Gritstone Bio Inc
13 Jan 20
Other Events
6:15am
patients receive nivolumab (anti-PD-1) GRANITE Phase 1: Dosing, Safety and Immunogenicity Rapid assessment of early clinical activity across advanced … assessment of early clinical activity with potential for quick to registration path in Phase 2 expansion cohorts
SLATE Prime/Boost Immunotherapy
8-K
EX-99.2
GRTS
Gritstone Bio Inc
4 Jan 22
Other Events
5:21pm
Patients with MSS-CRC PD < 24 weeks ctDNA assessment based on Gritstone-developed, tumor-informed assay ctDNA assessment not available for the 3
8-K
EX-10.1
m22pr6xayh3xq2
1 Feb 21
Entry into a Material Definitive Agreement
5:03pm
DEF 14A
9yihj
26 Apr 19
Definitive proxy
4:15pm
10-K
ovlckn
28 Mar 19
Annual report
4:01pm